These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 18081075)

  • 1. [The immunologic basis of vaccination. Hightech training for the immune system].
    Zündorf I; Vollmar AM; Dingermann T
    Pharm Unserer Zeit; 2008; 37(1):20-7. PubMed ID: 18081075
    [No Abstract]   [Full Text] [Related]  

  • 2. Vaccines and the infant's immune system--what nurses need to know.
    Heurter H; Langman E
    Can Nurse; 2005 Jan; 101(1):15-7. PubMed ID: 15776712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Innate immunity and new adjuvants.
    Mutwiri G; Gerdts V; Lopez M; Babiuk LA
    Rev Sci Tech; 2007 Apr; 26(1):147-56. PubMed ID: 17633299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Harnessing the beneficial heterologous effects of vaccination.
    Goodridge HS; Ahmed SS; Curtis N; Kollmann TR; Levy O; Netea MG; Pollard AJ; van Crevel R; Wilson CB
    Nat Rev Immunol; 2016 Jun; 16(6):392-400. PubMed ID: 27157064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How do adjuvants work? Important considerations for new generation adjuvants.
    McKee AS; Munks MW; Marrack P
    Immunity; 2007 Nov; 27(5):687-90. PubMed ID: 18031690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The possible reasons for the similarity of the immune and nervous systems].
    Abramov VV
    Usp Fiziol Nauk; 1990; 21(2):111-20. PubMed ID: 2198732
    [No Abstract]   [Full Text] [Related]  

  • 7. [The immunopathophysiology of burn trauma].
    Köller M; König W
    Dtsch Med Wochenschr; 1991 Jan; 116(2):67-73. PubMed ID: 1985811
    [No Abstract]   [Full Text] [Related]  

  • 8. Generic construction of single component particles that elicit humoural and cellular immune responses without the need for adjuvants.
    White PJ; Anastasopoulos F; Church JE; Kuo CY; Boyd BJ; Hickey PL; Tu LS; Burns P; Lew AM; Heath WR; Davey GM; Pouton CW
    Vaccine; 2008 Dec; 26(52):6824-31. PubMed ID: 18948160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The importance of the second generation adjuvanted systems in "new" vaccines].
    Beran J
    Klin Mikrobiol Infekc Lek; 2008 Feb; 14(1):5-12. PubMed ID: 18327735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CpG oligonucleotide, host defense peptide and polyphosphazene act synergistically, inducing long-lasting, balanced immune responses in cattle.
    Kovacs-Nolan J; Mapletoft JW; Latimer L; Babiuk LA; Hurk Sv
    Vaccine; 2009 Mar; 27(14):2048-54. PubMed ID: 19428829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strategies to link innate and adaptive immunity when designing vaccine adjuvants.
    Garlapati S; Facci M; Polewicz M; Strom S; Babiuk LA; Mutwiri G; Hancock RE; Elliott MR; Gerdts V
    Vet Immunol Immunopathol; 2009 Mar; 128(1-3):184-91. PubMed ID: 19042032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Development of the immune system].
    Durandy A
    Pathol Biol (Paris); 1992 Sep; 40(7):685-9. PubMed ID: 1480402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune states in long-term space flights.
    Ginsberg HS
    Life Sci Space Res; 1971; 9():1-9. PubMed ID: 12206176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The targeting of effector molecules in the immune system.
    Janeway CA
    Bioessays; 1986 Nov; 5(5):216-20. PubMed ID: 3492996
    [No Abstract]   [Full Text] [Related]  

  • 15. Vaccine Ingredients: Components that Influence Vaccine Efficacy.
    Kocourkova A; Honegr J; Kuca K; Danova J
    Mini Rev Med Chem; 2017; 17(5):451-466. PubMed ID: 27488583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune mechanisms in atherosclerosis and potential for an atherosclerosis vaccine.
    Chyu KY; Nilsson J; Shah PK
    Discov Med; 2011 May; 11(60):403-12. PubMed ID: 21616039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Natural immunity and animal welfare policies].
    Stegeman A
    Tijdschr Diergeneeskd; 2007 Oct; 132(19):768-9. PubMed ID: 17966328
    [No Abstract]   [Full Text] [Related]  

  • 18. Improved vaccines through targeted manipulation of the body's immunological risk-assessment?
    Sander LE
    Bioessays; 2012 Oct; 34(10):876-84. PubMed ID: 22815215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Vaccinations. Immunologic basis, indications, efficacy, complications].
    Beytout J
    Rev Prat; 2003 Sep; 53(14):1595-604. PubMed ID: 15185669
    [No Abstract]   [Full Text] [Related]  

  • 20. Designer adjuvants for enhancing the efficacy of infectious disease and cancer vaccines based on suppression of regulatory T cell induction.
    Mills KH
    Immunol Lett; 2009 Feb; 122(2):108-11. PubMed ID: 19100777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.